Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.

Download Full-text

Konsolidierungstherapie beim follikulären Lymphom: Längeres Überleben ohne Progress

Onkologische Welt ◽

10.1055/s-0038-1630995 ◽

2010 ◽

Vol 01 (03) ◽

pp. 144-144

Author(s):

Alexander Kretzschmar

Keyword(s):

Quantitative Pcr ◽

Ibritumomab Tiuxetan

Der Vorteil einer Konsolidierungstherapie mit 90Yttrium-Ibritumomab-Tiuxetan (Zevalin®) beim follikulären Lymphom (FL) wurde in der FIT-Studie anhand der Verbesserung des progressionsfreien Überlebens belegt. Eine quantitative PCR-Analyse (qPCR) der Studie zeigt nun einen weiteren Vorteil der Konsolidierung mit 90Yttrium- Ibritumomab-Tiuxetan: Der Antikörper führt bei 90% der initial bcl-2- positiven Patienten zur bcl-2- Negativität und parallel zu einer Verlängerung des progressionsfreien Überlebens auf über 40 Monate.

Download Full-text

Hepatitis G Viral RNA in Serum and in Peripheral Blood Mononuclear Cells and Its Relation to HCV-RNA in Patients with Clotting Disorders

Thrombosis and Haemostasis ◽

10.1055/s-0038-1656069 ◽

1997 ◽

Vol 77 (05) ◽

pp. 0868-0872 ◽

Cited By ~ 12

Author(s):

Li Sheng ◽

Ann Soumillion ◽

Kathelijne Peerlinck ◽

Chris Verslype ◽

Lan Lin ◽

...

Keyword(s):

Peripheral Blood Mononuclear Cells ◽

Peripheral Blood ◽

Mononuclear Cells ◽

Elevated Serum ◽

Normal Serum ◽

Hcv Rna ◽

Peripheral Blood Mononuclear ◽

Hepatitis G Virus ◽

Blood Mononuclear Cells ◽

Hepatitis G

SummaryThe hepatitis G virus (HGV) has recently been identified as a new member of the Flaviviridae family. Infection by this virus is thought to be associated with blood borne hepatitis. In this study, the presence of HCV- and HGV-RNAs in serum or plasma (175 patients) and in peripheral blood mononuclear cells (PBMC) (133 patients) was investigated in patients with clotting disorders using a sensitive reverse transcriptase polymerase chain reaction (RT-PCR). HGV-RNA was detected in serum of 26 patients (14.8%). In apparently healthy blood donors, serum HGV-RNA was detected in 4 of 358 individuals investigated (1.12%). Ninety two percent of the 26 serum HGV-RNA positive patients had coinfection with the hepatitis C virus (HGV), especially with HCV genotype lb, the most common genotype in Belgium. Of these coinfected patients, 15 (62.5%) showed elevated serum ALT levels. Two patients who were solely infected with HGV had normal serum ALT. HGV-RNA in PBMC was found in 18 patients, of whom 3 were negative for serum HGV-RNA. As in case of HCV, HGV-RNA in PBMC is preferentially sensitive to interferon treatment. Nevertheless, rapid reappearance of HGV-RNA in PBMC was observed after cessation of treatment. In one patient, persistent serum ALT elevation seems to be associated with continued HGV viremia, despite the disappearance of serum HCV-RNA.

Download Full-text

X-LINKED PSYCHOMOTOR DELAY AND ELEVATED SERUM T3 LEVELS CAUSED BY MUTATIONS IN THE MCT8 GENE: DELINEATION OF THE CLINICAL SYNDROME

Neuropediatrics ◽

10.1055/s-2006-943568 ◽

2006 ◽

Vol 37 (S 1) ◽

Author(s):

J Jansen ◽

W Arts ◽

E Friesema ◽

T Visser

Keyword(s):

Elevated Serum ◽

Clinical Syndrome ◽

Psychomotor Delay ◽

Serum T3

Download Full-text

SERUM THYROTROPHIN AND THE RESPONSE TO THYROTROPHIN RELEASING HORMONE IN SYMPTOMLESS AUTOIMMUNE THYROIDITIS AND IN BORDERLINE AND OVERT HYPOTHYROIDISM

Acta Endocrinologica ◽

10.1530/acta.0.0750274 ◽

1974 ◽

Vol 75 (2) ◽

pp. 274-285 ◽

Cited By ~ 42

Author(s):

A. Gordin ◽

P. Saarinen ◽

R. Pelkonen ◽

B.-A. Lamberg

Keyword(s):

Autoimmune Thyroiditis ◽

Elevated Serum ◽

Mean Value ◽

Primary Hypothyroidism ◽

Overt Hypothyroidism ◽

Thyrotrophin Releasing Hormone ◽

Releasing Hormone ◽

The Mean ◽

The Individual ◽

Serum Tsh

ABSTRACT Serum thyrotrophin (TSH) was determined by the double-antibody radioimmunoassay in 58 patients with primary hypothyroidism and was found to be elevated in all but 2 patients, one of whom had overt and one clinically borderline hypothyroidism. Six (29%) out of 21 subjects with symptomless autoimmune thyroiditis (SAT) had an elevated serum TSH level. There was little correlation between the severity of the disease and the serum TSH values in individual cases. However, the mean serum TSH value in overt hypothyroidism (93.4 μU/ml) was significantly higher than the mean value both in clinically borderline hypothyroidism (34.4 μU/ml) and in SAT (8.8 μU/ml). The response to the thyrotrophin-releasing hormone (TRH) was increased in all 39 patients with overt or borderline hypothyroidism and in 9 (43 %) of the 21 subjects with SAT. The individual TRH response in these two groups showed a marked overlap, but the mean response was significantly higher in overt (149.5 μU/ml) or clinically borderline hypothyroidism (99.9 μU/ml) than in SAT (35.3 μU/ml). Thus a normal basal TSH level in connection with a normal response to TRH excludes primary hypothyroidism, but nevertheless not all patients with elevated TSH values or increased responses to TRH are clinically hypothyroid.

Download Full-text